ReviewFrontiers in psychiatry2018
Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies.
Review in Frontiers in psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06432322 (Effects of Esketamine Challenge on Brain Glutamate Release), which is not on this map. Cited by 86 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Esketamine Challenge on Brain Glutamate Release (fMRS), Resting State Connectivity (BOLD-rs-fMRI), and Neuroplasticity (Visual Task)
Who cites it
86 citing papers in PubMed, 4 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- Functional MRS studies of GABA and glutamate/Glx - A systematic review and meta-analysis.Neuroscience and biobehavioral reviews · 2023Pooled it
- A genome-wide association study of suicide attempts in the million veterans program identifies evidence of pan-ancestry and ancestry-specific risk loci.Molecular psychiatry · 2022Pooled it
- Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.The Cochrane database of systematic reviews · 2021Pooled it
- Neurotoxic Effects of Neonicotinoids on Mammals: What Is There beyond the Activation of Nicotinic Acetylcholine Receptors?-A Systematic Review.International journal of molecular sciences · 2021Pooled it
- Widespread cortical thinning and subcortical alterations in mood and psychotic disorders across first-episode and chronic stages.Journal of affective disorders · 2026Article
- Targeting Pain and Depression in Alzheimer's Disease: Translational Insights and Emerging Treatments.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Curing the brain: in search for new astrocyte-specific therapies.Experimental & molecular medicine · 2026Review
- Sigma-1-targeting multimodal compound HBK-15 reverses memory deficits and restores hippocampal plasticity under NMDA hypofunction.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Therapeutic Values of General Anesthetics: From Developmental Neurotoxicity to Neurotherapeutic Agents.Current neuropharmacology · 2026Review
- Exploring New Frontiers in Pharmacological Treatment of Depression: A Review on Recent Advances.Current medicinal chemistry · 2026Review
- Impairment of Group I Metabotropic Glutamate Receptors in the Dorsal Striatum of the R451C-Neuroligin 3 Mouse Model of Autism Spectrum Disorder.Journal of neurochemistry · 2025Article
- Hydrogen sulfide/polysulfides signaling and neuronal diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Review
- Predicting antidepressant responsiveness in major depressive disorder patients via electroencephalography gamma-band dynamic functional connectivity in response to salient auditory stimuli.The international journal of neuropsychopharmacology · 2025Article
- Ultrasmall Superparamagnetic Magnetite Nanoparticles as Glutamate-Responsive Magnetic Resonance Sensors.Sensors (Basel, Switzerland) · 2025Article
- Ferroptosis as a potential molecular mechanism of bipolar disorder.Translational psychiatry · 2025Review
- Article
- Recent advances in bio-integrated electrochemical sensors for neuroengineering.Fundamental research · 2025Review
- Post stroke depression: pathogenesis and molecular mechanisms of natural product-based interventions.Frontiers in pharmacology · 2025Review
- Addressing brain metabolic connectivity in treatment-resistant schizophrenia: a novel graph theory-driven application ofSchizophrenia (Heidelberg, Germany) · 2024Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excessive glutamate release has been linked to stress and many neurodegenerative diseases. Evidence indicates abnormalities of glutamatergic neurotransmission or glutamatergic dysfunction as playing an important role in the development of many major psychiatric disorders (e.g., schizophrenia, bipolar disorder, and major depressive disorder). Recently, ketamine, an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.